NZ628756A - Immunogens for hiv vaccination - Google Patents

Immunogens for hiv vaccination

Info

Publication number
NZ628756A
NZ628756A NZ628756A NZ62875613A NZ628756A NZ 628756 A NZ628756 A NZ 628756A NZ 628756 A NZ628756 A NZ 628756A NZ 62875613 A NZ62875613 A NZ 62875613A NZ 628756 A NZ628756 A NZ 628756A
Authority
NZ
New Zealand
Prior art keywords
seq
nos
sequence
variant
immunogens
Prior art date
Application number
NZ628756A
Other languages
English (en)
Inventor
Christian Brander
Pujadas Beatriz Mothe
Anuska Llano
Original Assignee
Esteve Labor Dr
Fundació Privada Inst De Recerca De La Sida Caixa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr, Fundació Privada Inst De Recerca De La Sida Caixa filed Critical Esteve Labor Dr
Priority to NZ723229A priority Critical patent/NZ723229A/en
Publication of NZ628756A publication Critical patent/NZ628756A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ628756A 2012-01-27 2013-01-28 Immunogens for hiv vaccination NZ628756A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ723229A NZ723229A (en) 2012-01-27 2013-01-28 Immunogens for hiv vaccination

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12382031.8A EP2620446A1 (en) 2012-01-27 2012-01-27 Immunogens for HIV vaccination
PCT/EP2013/051596 WO2013110818A2 (en) 2012-01-27 2013-01-28 Immunogens for hiv vaccination

Publications (1)

Publication Number Publication Date
NZ628756A true NZ628756A (en) 2016-12-23

Family

ID=47603800

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ628756A NZ628756A (en) 2012-01-27 2013-01-28 Immunogens for hiv vaccination
NZ734689A NZ734689A (en) 2012-01-27 2013-01-28 Immunogens for hiv vaccination
NZ723229A NZ723229A (en) 2012-01-27 2013-01-28 Immunogens for hiv vaccination

Family Applications After (2)

Application Number Title Priority Date Filing Date
NZ734689A NZ734689A (en) 2012-01-27 2013-01-28 Immunogens for hiv vaccination
NZ723229A NZ723229A (en) 2012-01-27 2013-01-28 Immunogens for hiv vaccination

Country Status (16)

Country Link
US (4) US9988425B2 (enExample)
EP (3) EP2620446A1 (enExample)
JP (2) JP6306514B2 (enExample)
KR (2) KR102140778B1 (enExample)
CN (2) CN110372798A (enExample)
AU (2) AU2013213564B2 (enExample)
BR (1) BR112014018396B1 (enExample)
CA (1) CA2862172C (enExample)
ES (1) ES2932407T3 (enExample)
IL (2) IL233771B (enExample)
IN (1) IN2014DN06164A (enExample)
MX (2) MX358711B (enExample)
NZ (3) NZ628756A (enExample)
RU (2) RU2721274C2 (enExample)
WO (1) WO2013110818A2 (enExample)
ZA (1) ZA201405204B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9090673B2 (en) * 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
WO2015140774A1 (en) * 2014-03-21 2015-09-24 Nutech Ventures A non-naturally occuring porcine reproductive and respiratory syndrome virus (prrsv) and methods of using
SI3166607T1 (sl) 2014-07-11 2023-01-31 Gilead Sciences, Inc. Modulatorji toličnih receptorjev za zdravljenje HIV-a
CN110305133A (zh) 2014-09-16 2019-10-08 吉利德科学公司 Toll样受体调节剂的固体形式
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
US20220226459A1 (en) * 2019-05-22 2022-07-21 Aelix Therapeutics, S.L. Dosage regimens for vaccines
CN113924114A (zh) 2019-05-22 2022-01-11 吉利德科学公司 Tlr7调节化合物和hiv疫苗的组合
AU2020315598B2 (en) 2019-07-16 2024-12-12 Gilead Sciences, Inc. HIV vaccines and methods of making and using
AU2020384323A1 (en) 2019-11-14 2022-06-02 Aelix Therapeutics, S.L. Dosage regimens for vaccines
CA3182703A1 (en) 2020-05-12 2021-11-18 Janssen Vaccines & Prevention B.V. Administration of homologous adenoviral vectors
WO2022084333A1 (en) 2020-10-20 2022-04-28 Janssen Vaccines & Prevention B.V. Hiv vaccine regimens
CA3202466A1 (en) 2021-01-14 2022-07-21 Jiani LI Hiv vaccines and methods of using
WO2024084441A1 (en) 2022-10-19 2024-04-25 Aelix Therapeutics, S.L. Combination hiv vaccine
EP4417974A1 (en) 2023-02-17 2024-08-21 Fundació Privada Institut de Recerca de la SIDA-Caixa Cd33 as a biomarker of hiv control
WO2025017540A1 (en) 2023-07-20 2025-01-23 Aelix Therapeutics, S.L. Method of treatment of hiv infection with vaccine
CN118389553A (zh) * 2024-03-01 2024-07-26 中国科学技术大学 免疫增效rna分子及其组合物、疫苗与试剂盒

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE787901A (fr) 1971-09-11 1972-12-18 Freistaat Bayern Represente Pa Vaccin antivariolique
US6610476B1 (en) 1984-08-22 2003-08-26 The United States Of America As Represented By The Department Of Health And Human Services Detection of HIV-1 DNA
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US6294322B1 (en) 1988-01-26 2001-09-25 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1
US5976541A (en) 1988-01-26 1999-11-02 The United States Of America As Represented By The Department Of Health And Human Services Potent peptide for stimulation of cytotoxic T lymphocytes specific for the HIV-1 envelope
US5081226A (en) 1986-12-30 1992-01-14 The United States Of America As Represented By The Department Of Health And Human Services Synthetic peptides sharing sequence homology with the HIV envelope protein
US6210873B1 (en) 1987-08-28 2001-04-03 Board Of Regents, The University Of Texas System Methods and compositions for the priming of specific cytotoxic T-lymphocyte response
US5128319A (en) 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
GB8918200D0 (en) 1989-08-09 1989-09-20 Medical Res Council The peptide fragments of hiv
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US7319000B1 (en) 1992-09-16 2008-01-15 Board Of Regents, The University Of Texas System Compositions and methods for eliciting immune or anti-infective responses
AU693098B2 (en) 1993-06-09 1998-06-25 Connaught Laboratories Limited Tandem synthetic HIV-1 peptides
KR20050052548A (ko) 1994-12-24 2005-06-02 캠브리지 유니버시티 테크니칼 서비스 리미티드 자궁내막기능 또는 자궁내막기능과 관련된 기능의 개선방법
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US6093400A (en) 1996-08-09 2000-07-25 Cel Sci Corporation Modified HGP-30 peptides, conjugates, compositions and methods of use
CA2262432A1 (en) 1996-08-09 1998-02-19 Viral Technologies, Inc. Hiv p-17 peptide fragment, compositions containing and methods for producing and using same
US6031647A (en) 1996-10-23 2000-02-29 Nortel Networks Corporation Stable power control for optical transmission systems
US5972339A (en) 1997-11-13 1999-10-26 The General Hospital Corporation Method of eliciting anti-HIV-1 helper T cell responses
US20040106136A1 (en) 1999-01-25 2004-06-03 Musc Foundation For Research Development Method for testing drug susceptibility of HIV
CN1297932A (zh) * 1999-11-30 2001-06-06 上海博容基因开发有限公司 一种新的多肽——人脂蛋白前体蛋白信号肽11和编码这种多肽的多核苷酸
DK1240186T3 (da) * 1999-12-23 2010-05-31 Medical Res Council Forbedringer i eller relateret til immunrespons mod HIV
FR2803307A1 (fr) * 1999-12-30 2001-07-06 Centre Nat Rech Scient Lignees de lymphocytes t cd4 specifiques de type th1 et procede pour leur induction ex vivo
US20040105871A1 (en) 2000-03-02 2004-06-03 Robinson Harriet L. Compositions and methods for generating an immune response
CN1312275A (zh) * 2000-03-07 2001-09-12 上海博德基因开发有限公司 一种新的多肽——人热休克蛋白15和编码这种多肽的多核苷酸
EP1278541A1 (en) 2000-04-28 2003-01-29 The Government of The United States of America, as represented by The Department of Health and Human Services Improved immunogenicity using a combination of dna and vaccinia virus vector vaccines
ATE318908T1 (de) 2000-05-18 2006-03-15 Geneart Gmbh Synthetische gene für gagpol und deren verwendungen
AUPQ776100A0 (en) 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
EP2302059A1 (en) * 2000-08-14 2011-03-30 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Modifications of hiv Env, Gag, and Pol enhance immunogenicity for genetic immunization
HU230198B1 (hu) 2000-11-23 2015-10-28 Bavarian Nordic A/S Módosított Vacciniavírus Ankara-variáns
CU23235A1 (es) 2001-02-28 2007-09-26 Ct Ingenieria Genetica Biotech POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA
JP4601956B2 (ja) 2001-09-20 2010-12-22 グラクソ グループ リミテッド Ｈｉｖ−ｇａｇのコドン最適化ｄｎａワクチン
AUPR842501A0 (en) 2001-10-23 2001-11-15 Epipop Pty Ltd A method for identification and development of therapeutic agents
US20050266024A1 (en) 2002-03-19 2005-12-01 Powdermed Limited Adjuvant
RU2238946C2 (ru) * 2002-04-22 2004-10-27 Государственный научный центр вирусологии и биотехнологии "Вектор" Искусственный белок-иммуноген tci, содержащий множественные ctl-эпитопы основных антигенов вич-1, искусственный ген tci, кодирующий полиэпитопный белок-иммуноген tci
CN1325512C (zh) 2002-05-16 2007-07-11 巴法里安诺迪克有限公司 Hiv调节/辅助蛋白的融合蛋白
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
UA82479C2 (uk) 2002-05-16 2008-04-25 Бавариан Нордика А/С Міжгенні регіони як сайти вставки в геном модифікованого вірусу коров'ячої віспи ankara (mva)
WO2004002415A2 (en) 2002-06-27 2004-01-08 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating a cytotoxic t lymphocyte immune response
EP1638993A4 (en) 2003-06-10 2007-05-09 Univ Melbourne IMMUNOMODULATING COMPOSITIONS, APPLICATIONS THEREOF AND METHOD FOR THE PRODUCTION THEREOF
CA2539325C (en) 2003-09-17 2016-03-22 Duke University Consensus/ancestral immunogens
EP1678292A4 (en) 2003-09-18 2008-05-07 Univ Emory IMPROVED MVA VACCINES
AU2004276559A1 (en) * 2003-09-24 2005-04-07 Oxxon Therapeutics Limited HIV pharmaccines
GB0323840D0 (en) 2003-10-10 2003-11-12 Ist Superiore Sanita Vaccines
EP1687022A4 (en) 2003-11-12 2008-02-13 Medical Res Council RENTA: HIV IMMUNOGENIC AND ITS APPLICATIONS
WO2006010106A2 (en) * 2004-07-09 2006-01-26 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services Dna-based vaccination of retroviral-infected individuals undergoing treatment
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
WO2006026667A2 (en) 2004-08-27 2006-03-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant mva viruses expressing glade a/g, clade b, and clade c modified hiv, gag and pol genes
US8000900B2 (en) 2004-09-21 2011-08-16 Microsoft Corporation Association-based predictions of pathogen characteristics
US20060095241A1 (en) 2004-10-29 2006-05-04 Microsoft Corporation Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
US8478535B2 (en) 2004-10-29 2013-07-02 Microsoft Corporation Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
US20060160070A1 (en) 2004-10-29 2006-07-20 Microsoft Corporation Association-based epitome design
EP2243788A1 (en) 2005-02-24 2010-10-27 Medical Research Council HIVCON: An HIV immunogen and uses thereof
WO2007008780A2 (en) * 2005-07-11 2007-01-18 Globeimmune, Inc. Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
BRPI0504117A (pt) 2005-09-05 2007-05-22 Fundacao De Amparo A Pesquisa epìtopos, combinação de epìtopos, usos de epìtopos ou sua combinação, composição, usos da composição, vacinas profiláticas anti-hiv-1, vacinas terapêuticas, método para a identificação de epìtopos e métodos para o tratamento ou prevenção
SG170092A1 (en) 2006-03-10 2011-04-29 Peptcell Ltd Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof
GB0608368D0 (en) 2006-04-28 2006-06-07 Isis Innovation Process for making Oligopeptides
EP2023954B1 (en) 2006-05-19 2013-07-17 Sanofi Pasteur, Inc. Immunological composition
DK2402451T3 (en) 2006-08-25 2018-06-25 The Government Of The Us Secretary Department Of Health And Human Services Method for Stabilizing a DNA Insert in a Recombinant Vaccine Vector
WO2008117813A1 (ja) 2007-03-28 2008-10-02 Hiroshima University ニワトリ胚性幹細胞およびその評価方法
JP5345135B2 (ja) * 2007-04-26 2013-11-20 メルク・シャープ・アンド・ドーム・コーポレーション 昆虫細胞のための合成の発現ベクター
WO2009009743A2 (en) * 2007-07-12 2009-01-15 Institute For Advance Study Sequence optimization for expression of a foreign gene
CA2711145A1 (en) 2008-01-16 2009-07-23 Opal Therapeutics Pty Ltd Immunomodulating compositions and uses therefor
WO2010009346A2 (en) * 2008-07-16 2010-01-21 Baylor Research Institute Hiv vaccine based on targeting maximized gag and nef to dendritic cells
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
US8709775B2 (en) 2008-08-29 2014-04-29 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
EP2161279A1 (en) 2008-08-29 2010-03-10 Centre National de la Recherche Scientifique Synthetic peptides corresponding to overlapping neutralizing determinants in the CBD1 epitope induce broadly neutralizing antibodies
WO2010037402A1 (en) * 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
PL2358757T3 (pl) 2008-11-18 2019-02-28 Beth Israel Deaconess Medical Center Szczepionki antywirusowe o ulepszonej immunogenności komórkowej
EP2477651A1 (en) 2009-09-17 2012-07-25 Sanofi Pasteur Inc. Immunological compositions for hiv
JP2013507107A (ja) * 2009-10-08 2013-03-04 バヴァリアン・ノルディック・アクティーゼルスカブ Ｈｉｖに対するヒトにおける広範なｔ細胞応答の生成
WO2011047324A1 (en) 2009-10-16 2011-04-21 The U.S.A. As Represented By The Secretary , Department Of Health And Human Services . Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites
US20130195904A1 (en) 2010-01-04 2013-08-01 National University Of Singapore Human immunodeficiency virus (hiv-1) highly conserved and low variant sequences as targets for vaccine and diagnostic applications
EP2638060A2 (en) 2010-11-10 2013-09-18 Laboratorios Del Dr. Esteve, S.A. Highly immunogenic hiv p24 sequences
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
US20220226459A1 (en) 2019-05-22 2022-07-21 Aelix Therapeutics, S.L. Dosage regimens for vaccines
CN113924114A (zh) 2019-05-22 2022-01-11 吉利德科学公司 Tlr7调节化合物和hiv疫苗的组合
AU2020384323A1 (en) 2019-11-14 2022-06-02 Aelix Therapeutics, S.L. Dosage regimens for vaccines

Also Published As

Publication number Publication date
BR112014018396A8 (pt) 2017-07-11
AU2018203264A1 (en) 2018-05-31
WO2013110818A2 (en) 2013-08-01
RU2018104969A3 (enExample) 2019-02-22
RU2648791C2 (ru) 2018-04-02
US9988425B2 (en) 2018-06-05
BR112014018396B1 (pt) 2023-03-21
IL268629A (en) 2019-10-31
KR20140122735A (ko) 2014-10-20
RU2018104969A (ru) 2019-02-22
US20190055289A1 (en) 2019-02-21
NZ723229A (en) 2019-03-29
MX2014009091A (es) 2014-11-10
IL268629B (en) 2021-06-30
AU2013213564A1 (en) 2014-09-04
CA2862172A1 (en) 2013-08-01
IL233771A0 (en) 2014-09-30
US20180170971A1 (en) 2018-06-21
MX2018010483A (es) 2020-09-02
BR112014018396A2 (enExample) 2017-06-20
US20210246172A1 (en) 2021-08-12
US20150050310A1 (en) 2015-02-19
EP2620446A1 (en) 2013-07-31
JP6306514B2 (ja) 2018-04-04
US10815278B2 (en) 2020-10-27
US11919926B2 (en) 2024-03-05
KR102108149B1 (ko) 2020-05-12
MX358711B (es) 2018-08-31
ES2932407T3 (es) 2023-01-18
ZA201405204B (en) 2015-10-28
RU2721274C2 (ru) 2020-05-18
IN2014DN06164A (enExample) 2015-08-21
RU2014135053A (ru) 2016-03-27
CN104080800A (zh) 2014-10-01
KR20190085552A (ko) 2019-07-18
CA2862172C (en) 2023-07-18
EP2807185B1 (en) 2022-09-14
AU2013213564B2 (en) 2018-03-29
EP2807185A2 (en) 2014-12-03
JP2015509707A (ja) 2015-04-02
CN110372798A (zh) 2019-10-25
AU2018203264B2 (en) 2019-07-11
HK1204632A1 (en) 2015-11-27
KR102140778B1 (ko) 2020-08-06
IL233771B (en) 2019-08-29
WO2013110818A3 (en) 2013-11-07
US11325946B2 (en) 2022-05-10
JP6749357B2 (ja) 2020-09-02
CN104080800B (zh) 2019-08-27
EP4163290A1 (en) 2023-04-12
JP2018102314A (ja) 2018-07-05
NZ734689A (en) 2022-09-30

Similar Documents

Publication Publication Date Title
NZ723229A (en) Immunogens for hiv vaccination
NZ607870A (en) Lactococcus crispr-cas sequences
MX2018016114A (es) Una novedosa fructosa-6-fosfato-3-epimerasa termoestable y un procedimiento para producir alulosa mediante el uso de la misma.
NZ702145A (en) Bluetongue virus recombinant vaccines and uses thereof
NZ701125A (en) Improved chymosine enzyme variants
NZ602845A (en) Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof
HK1198170A1 (en) Pseudomonas exotoxin a with less immunogenic b cell epitopes
WO2014202622A3 (en) Rasamsonia gene and use thereof
NZ597442A (en) Hyr1 as a target for active and passive immunization against candida
WO2015185758A3 (en) Preparation comprising factor viii and von willebrand factor peptides
IN2014DN09963A (enExample)
MX2015001542A (es) Metodo.
GB201017519D0 (en) Vaccines
EP4067485A3 (en) Lipase variants and polynucleotides encoding same
NZ703514A (en) Fviii peptides for immune tolerance induction and immunodiagnostics
MY187334A (en) Xylanase
WO2010057242A3 (de) Vakzin
EP4043558A3 (en) Kaurenoic acid hydroxylases
EP4282960A3 (en) Modified lipase and use thereof
AR083766A1 (es) Peptido inmunogenico
WO2009072555A1 (ja) 癌ワクチン
PH12013501105A1 (en) Tomm34 peptides and vaccines including the same
NZ600978A (en) Vaccine compositions
WO2014202623A3 (en) Rasamsonia gene and use thereof
GB201121615D0 (en) Synthesis of n-acetyl-d-neuraminic acid

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: FUNDACIA PRIVADA INSTITUT DE RECERCA DE LA SI, ES

Effective date: 20160728

Owner name: LABORATORIOS DEL DR. ESTEVE, S.A., ES

Effective date: 20160728

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 28 JAN 2020 BY COLLISON + CO

Effective date: 20170420

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JAN 2021 BY CPA GLOBAL

Effective date: 20191212

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JAN 2022 BY CPA GLOBAL

Effective date: 20201218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JAN 2023 BY CPA GLOBAL

Effective date: 20211216

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JAN 2024 BY CPA GLOBAL

Effective date: 20221216

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JAN 2025 BY CPA GLOBAL

Effective date: 20231214

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JAN 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20241212

ASS Change of ownership

Owner name: FUNDACIO PRIVADA INSTITUT DE RECERCA DE LA SID, ES

Effective date: 20251211

Owner name: CORPORACION QUIMICO-FARMACEUTICA ESTEVE S.A., ES

Effective date: 20251211

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JAN 2027 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20251211